Effects of Telemonitoring Service for Obesity Care (Smart-OB)
A Randomized, Open, Parallel, Multi-center Trial to Evaluate Weight Loss Efficacy of Smart Care Service in Obese Patients With Metabolic Syndrome.
調査の概要
詳細な説明
- Objectives : To evaluate superiority of U(Ubiquitous)-Healthcare(hereinafter referred to as Smart Care) Service being combined conventional treatment with health care service, in comparison to conventional treatment in obese patients with metabolic syndrome.
Test and control group
- Test groups : The subject group who is receiving health care services using conventional treatment (hospital visit) and Smart Care Service (Telemonitoring).
- Control group : The subject group who is receiving conventional treatment (hospital visit).
- Target Subject: Obese patients with metabolic syndrome.
研究の種類
入学 (実際)
段階
- 適用できない
連絡先と場所
研究場所
-
-
-
Seoul、大韓民国
- Seoul National University Hospital
-
Seoul、大韓民国
- Yonsei University Health System
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Age: More than 20 years of age and under 70 years of age.
- BMI ≥ 25kg/m2
Patients with metabolic syndrome (who have more than three of following 5 components of metabolic syndrome) and who are able to receive outpatient treatment.
A. Abdominal obesity: Waist circumference≥90cm(Male), 85cm(Female) B. Patients whose blood pressure ≥130/85mmHg(systolic blood pressure over 130 or, diastolic blood pressure over 85) or patients who are taking blood pressure medication.
C. Fasting Blood Glucose (FPG)≥ 100mg/dl. D. Patients whose triglyceride ≥150 mg/dl or patients who are taking fibrate. E. High-density lipoprotein cholesterol (HDL) < 40 mg/dl (Male), 50 mg/dl(Female)
- Patients who are able to understand the purpose of this trial and to read and write.
- Patients who are able to use U-healthcare Smartphone for this trial.
- Patients who participate voluntarily and sign the informed consent.
Exclusion Criteria:
- Type I diabetes mellitus patients and type II diabetes mellitus patients requiring insulin therapy.
- Patients currently being hospitalized or planning to hospitalize during the study period.
- Patients were diagnosed with myocardial infarction or stroke within 1 year
- End Stage Renal Disease patients requiring renal replacement therapy, Serum creatinine level is greater than 1.5 times the upper limit of normal.
- Females who are pregnant
- Hepatic failure (severe hepatic dysfunction). Liver Function Test (AST or ALT) is greater than 3 times the upper limit of normal.
- Uncontrolled chronic lung disease.
- Patients with known gallstone.
- Patients who have cognitive disorder or psychiatric problems.
- Patients who are taking anti-obesity medications such as Reductil, Xenical, etc., or patients are planning to receive the medications.
- Patients who are taking Synthroid, diabetes medications or psychiatric medications which may affect on body weight.
- Any clinically significant medical condition including neurologic disease, gastrointestinal disease or malignant tumor, etc., which may affect the test results, or any other medical condition which in the opinion of the investigator makes the patients unsuitable for participation in the trial.
- Patients who have participated in other clinical trial (except for the observational study) within 12 weeks prior to screening visit.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:支持療法
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
---|---|
実験的:Telemonitoring group
|
The Telemonitoring group will be provided the Smartphone, body composition analyzer and pedometer.
They should visit the site once per every 3 months (12 weeks), and measure their body composition during study period.
After measurement of body composition, the subjects should make transmit measured information through Smartphone into a centralized server of Smart Care Center.
At Smart care Center, care manager will provide remote body composition and activity monitoring and individual obesity case management
他の名前:
|
他の:Control group
|
The control group will receive a weighting scale and pedometer.
They should perform the same weight measurement (minimum three times a week) like the intervention group during the study, and measured results should be recorded in a diary of self body weight and the number of steps.
In addition, the subjects should visit the site once per every three months (12 weeks).
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
時間枠 |
---|---|
Weight Change from Baseline to 24 weeks
時間枠:0 and 24 weeks
|
0 and 24 weeks
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
Body Mass Index (BMI) changes
時間枠:0 and 24 weeks
|
Reduces of body mass index - BMI=Body weight (kg)/Height2(m) |
0 and 24 weeks
|
Proportion of subjects whose body weight decreased more than 10%
時間枠:0 and 24 weeks
|
0 and 24 weeks
|
|
Changes in body fat rate
時間枠:0 and 24 weeks
|
Reduces in body fat rate
|
0 and 24 weeks
|
Changes in waist circumference
時間枠:0 and 24 weeks
|
Reduces waist circumference
|
0 and 24 weeks
|
Changes in lipid profile
時間枠:0 and 24 weeks
|
Changes in lipid profile(total cholesterol, HDL cholesterol, LDL cholesterol triglycerides)
|
0 and 24 weeks
|
Changes in blood pressure
時間枠:0 and 24 weeks
|
Blood pressure value when hospital visiting
|
0 and 24 weeks
|
Changes in prevalence rate of metabolic syndrome
時間枠:0 and 24 weeks
|
0 and 24 weeks
|
|
Changes in the number of metabolic syndrome components
時間枠:0 and 24 weeks
|
Reduce the number of metabolic syndrome components
|
0 and 24 weeks
|
Changes in lifestyle
時間枠:0 and 24 weeks
|
Changes in lifestyle such as smoking, drinking, dietary and physical activity, etc
|
0 and 24 weeks
|
Patients' satisfaction
時間枠:24 weeks
|
applicable to Only Telemonitoring group
|
24 weeks
|
協力者と研究者
スポンサー
捜査官
- 主任研究者:Bi-Ryong Cho、Seoul National University Hospital
出版物と役立つリンク
一般刊行物
- Oh B, Yi GH, Han MK, Kim JS, Lee CH, Cho B, Kang HC. Importance of Active Participation in Obesity Management Through Mobile Health Care Programs: Substudy of a Randomized Controlled Trial. JMIR Mhealth Uhealth. 2018 Jan 3;6(1):e2. doi: 10.2196/mhealth.8719.
- Oh B, Cho B, Han MK, Choi H, Lee MN, Kang HC, Lee CH, Yun H, Kim Y. The Effectiveness of Mobile Phone-Based Care for Weight Control in Metabolic Syndrome Patients: Randomized Controlled Trial. JMIR Mhealth Uhealth. 2015 Aug 20;3(3):e83. doi: 10.2196/mhealth.4222.
研究記録日
主要日程の研究
研究開始
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。